TGFB1 and plasma cell myeloma: In U266-GFP-Luc cell–transplanted NSG mice, MMBD was serially evaluated using in vivo micro–computed tomography (microCT), and it showed the antiresorptive capacity of transforming growth factor β (TGF-β) receptor I kinase inhibitor (SD-208) by prevention and treatment of myeloma bone lesions via enhancing collagen matrix maturation (Green et al., 2019).